Anton Rx Report

We’ve often written about the legal pitfalls that specialty pharmacies may encounter that end up costing them financially (HIPAA violations are top of mind). Today

Earlier this month the FDA approved a ‘new’ combination therapy, Darzalex Faspro (daratumumab and hyaluronidase-fihj), from Janssen Biotech. Darzalex was originally approved in 2015 with

It’s about time.It has been quite a while since we’ve heard about a specialty pharmacy acquisition. Over recent years there was a race to the

The public relations battle surrounding White Bagging is heating up.Who’s on each side?Depends on who you ask….!On one side, hospitals are claiming that their very

Here’s something that you don’t see every day….. We published the report below in November 2019 detailing the approval of Exservan, a drug first approved

We missed one….!The drug being recapped today was approved back in late February. We put it on the shelf till we could determine whether this

The FDA recently approved a specialty ORAL therapy, Truseltiq (infigratinib) from QED Therapeutics (one of several BridgeBio affiliates). Truseltiq was granted an indication for unresectable

Get yer Lumakras!Lumakras here! 90+% of FDA specialty approvals launched through limited distribution in 2011….. and that trend continues in 2021. As frequent readers know,

In a flood of approvals in the last days of May the FDA green lighted a new ORAL therapy, Lumakras (sotorasib) from Amgen, three months

The FDA approval of the new therapy for Alzheimer’s is like no other in recent memory and has generated a firestorm reaction from both supporters